DaVita

DaVita Inc. (NYSE: DVA) operates as a leading global healthcare provider specializing in kidney care services. The company maintains its corporate presence at davita.com and serves patients across the United States and internationally through a comprehensive platform addressing chronic kidney disease management and end-stage renal disease treatment.

The company's business is organized into three primary segments. The U.S. dialysis business represents approximately 86 percent of consolidated revenues and constitutes the largest operating division. As of December 31, 2025, DaVita operated 2,657 outpatient dialysis centers across 46 states and the District of Columbia, treating approximately 200,500 patients. The company provides hemodialysis services, peritoneal dialysis support, home hemodialysis services, hospital inpatient dialysis through contracts with approximately 740 hospitals, and specialized laboratory testing for end-stage renal disease patients. The U.S. dialysis business also generates revenue through medical director services and management fees for centers in which DaVita holds noncontrolling interests.

The U.S. integrated kidney care business provides disease management and care coordination services to approximately 75,400 patients through risk-based and value-based care arrangements, including participation in Medicare Advantage chronic special needs plans and the Center for Medicare and Medicaid Innovation's Comprehensive Kidney Care Contracting model. This segment focuses on managing patients across the kidney disease continuum from early-stage chronic kidney disease through end-stage renal disease and transplantation.

International operations comprise the third segment, with 585 outpatient dialysis centers located across 14 countries serving approximately 94,500 patients. Major international markets include Brazil, Colombia, Malaysia, Poland, and Chile.

Revenue sources for U.S. dialysis services include Medicare and Medicare Advantage plans accounting for 57 percent, commercial insurance representing 32 percent, and Medicaid and other government programs comprising 11 percent. The company employs a patient-centric care model emphasizing clinical quality, with consistent recognition as an industry leader in the Centers for Medicare and Medicaid Services Quality Incentive Program and Five-Star Quality Rating System. DaVita maintains relationships with approximately 5,200 nephrologists and operates through joint venture partnerships with physicians and healthcare organizations.